A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

NCT01226732 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Metastatic or Unresectable Solid Tumor Malignancy

Interventions

DRUG: Capecitabine
DRUG: Hsp90 Inhibitor AUY 922

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]